NX-1207

DRUG5 trials

Sponsors

Nymox Corporation, RECORDATI GROUP

Conditions

BPHBenign Prostatic HyperplasiaBenign Prostatic Hyperplasia (BPH)LUTSLower Urinary Tract SymptomsLower Urinary Tract Symptoms (LUTS)

Phase 3

Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)

CompletedNCT00918983

Nymox CorporationBenign Prostatic Hyperplasia

Start: 2009-04-30End: 2013-11-30Updated: 2014-04-30

Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018

CompletedNCT00945490

Nymox CorporationBenign Prostatic Hyperplasia (BPH)

Start: 2009-05-31End: 2014-05-31Updated: 2017-03-10

Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)

CompletedNCT01438775

Nymox CorporationBenign Prostatic Hyperplasia

Start: 2011-09-30End: 2013-01-31Updated: 2014-04-30

Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)

CompletedNCT01846793

Nymox CorporationBenign Prostatic Hyperplasia, BPH, Lower Urinary Tract Symptoms (LUTS) +1

Start: 2013-04-30End: 2014-10-31Updated: 2017-03-10

Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH

TerminatedNCT02003742

RECORDATI GROUPLower Urinary Tract Symptoms

Start: 2013-09-30End: 2015-01-29Updated: 2022-05-26